TIDMAGL
RNS Number : 3936L
Angle PLC
19 April 2018
For immediate release 19 April 2018
ANGLE plc ("the Company")
BREAKTHROUGH RESEARCH DEMONSTRATES PARSORTIX WORKFLOW FOR
CULTURING CIRCULATING TUMOR CELLS FOR IN-VITRO DRUG TESTING
Unique capabilities of ANGLE's Parsortix system address a key
aim of precision medicine to test drugs outside the patient to
determine which drugs will benefit the patient
Work highlights another major opportunity for the use of ANGLE's
Parsortix system in breast cancer post FDA clearance
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is delighted to announce that results presented by one of
the leading US cancer centers at the American Association for
Cancer Research conference (AACR) 2018, in Chicago have
demonstrated a workflow for culturing circulating tumor cells
(CTCs) using ANGLE's Parsortix(TM) system.
The innovative research undertaken by the Robert H Lurie
Comprehensive Cancer Center and the Feinberg School of Medicine,
Northwestern University, Chicago (Northwestern) has for the first
time developed an optimised workflow for the recovery and culturing
of CTCs from a simple blood test to produce an effective ex-vivo
culture (cells growing outside the patient) of the individual
patient's cancer cells. The team of investigators led by Dr.
Massimo Cristofanilli focused on demonstrating the capability to
interrogate and test cancer cells collected from patients with
advanced breast cancer. This achievement was only possible because
the epitope-independent (does not use antibodies) patented
microfluidic process used by the Parsortix system for CTC
enrichment harvests undamaged living CTCs, which can then be
cultured.
This is the first time that an optimised workflow has been
presented to culture CTCs ex-vivo. This has been a goal of many
research groups for some time but has not been achievable because
the methods of CTC isolation used yield low numbers of only
partially purified CTCs that are fixed before isolation (hence
killed), damaged during the cell purification process, or
irreversibly immobilised on an adherent matrix. The Parsortix
system neatly avoids all these problems providing a simple
reproducible way to harvest CTCs that can be cultured. This is
another example of the use of CTCs harvested using the Parsortix
system, which cannot be addressed using ctDNA. Previous culturing
of CTCs harvested from leukapheresis (transfusion of blood out and
back into the body taking up to an hour) product using Parsortix
has been reported but this is the first time it has been achieved
from a simple blood test.
Northwestern tested their ex-vivo culture workflow on 16
metastatic breast cancer patients. A single 7.5ml EDTA blood tube
was drawn from a simple blood test for each patient. In every
patient (100%), the Parsortix system yielded viable CTCs that could
be developed into an ex-vivo culture. The number of CTCs harvested
using the Parsortix system was significantly higher than has been
reported with other systems and ranged from 300 to 17,250 CTCs per
patient.
The CTCs were then successfully cultured over a three week
period at which time the DNA was isolated and purified. The CTCs in
culture retained their morphology and expanded 3.5 - 5.5 fold in
week one, and then 9.5 - 22.5 fold in week two yielding as many as
100,000 cancer cells within 14 days thus providing sufficient DNA
for a wide range of multiple analyses to be undertaken.
Northwestern's poster presentation to AACR 2018 is entitled "A
novel ex vivo culture workflow to enrich and expand circulating
tumor cells (CTCs) from patients with Stage III/IV Breast Cancer
(BCa) (LB-370)". A copy is available here
https://angleplc.com/library/publications/
The mutational profile of a patient's tumor evolves over time.
Consequently a non-invasive method to provide a series of ex-vivo
cultures of the patient's cancer cells for organoids development
and in-vitro drug testing enables the changing patterns of drug
susceptibility in individual patients to be monitored as their
tumors acquire new mutations. This would enable the patient to
receive the right drug at the right time, improving outcomes for
patients and avoiding wasted resources on drugs, which are
ineffective.
Professor Massimo Cristofanilli, MD Associate Director,
Translational Research - Robert H Lurie Comprehensive Cancer
Center, Northwestern University, commented:
"The ability to recover, culture and interrogate cancer cells
expands our possibility to advance precision medicine in breast
cancer patients. We believe that the optimisation of the workflow
utilising the Parsortix system to produce ex-vivo cultures of CTCs
is already opening up a new frontier in the management of breast
cancer, by allowing the testing of treatments in a 'predictive in
vitro system' truly representative of the patient's disease and
improving our ability to select agents and predict efficacy. Widely
adopted, this approach has the potential to transform the way we
treat cancer patients."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"This is the first time that CTCs have been successfully
cultured direct from a Parsortix processed whole blood sample. This
work is highly encouraging for ANGLE. Firstly every metastatic
breast sample analysed yielded a large number of CTCs, which is a
positive sign for our FDA study. Secondly, Northwestern has
achieved something that many other Centres before them have failed
to do, which is to produce an optimised workflow for reproducibly
growing the CTCs. This approach is potentially applicable for every
metastatic breast cancer patient and provides another clear high
value application for ANGLE's Parsortix system."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks,
Andrew Craig, Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Evan Smith, Anne Troy (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix system has a CE Mark for
Europe and FDA clearance is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of
all types is called Ziplex(R) and is based on a patented flow
through array technology. It provides for highly multiplexed, rapid
and sensitive capture of targets from a wide variety of sample
types. A proprietary chemistry allows for the capture and
amplification of over 100 biomarkers simultaneously in a single
reaction. These technologies can be combined to provide fully
automated, sample to answer results in both centralised laboratory
and point of use cartridge formats. It is ideal for measuring gene
expression and other markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESBVLLFVZFFBBV
(END) Dow Jones Newswires
April 19, 2018 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Angle (LSE:AGL)
Historical Stock Chart
From Sep 2023 to Sep 2024